Format

Send to

Choose Destination
Atheroscler Suppl. 2018 Jun;31:e1-e12. doi: 10.1016/j.atherosclerosissup.2018.04.001.

Standardization of laboratory and lipid profile evaluation: A call for action with a special focus in 2016 ESC/EAS dyslipidaemia guidelines - Full report.

Author information

1
Coordinator of the Cardiovascular Risk and Prevention Group of the Portuguese Internal Medicine Society, Arterial Investigation Unit, Medicine Department, Medicina 4, Hospital de Santa Marta - Centro Hospitalar de Lisboa Central, EPE, Lisboa, Portugal. Electronic address: pedro.silva@chlc.min-saude.pt.
2
General Secretary of the Portuguese Atherosclerosis Society, Endocrinology Department - Hospital de Egas Moniz, Centro Hospitalar de Lisboa Ocidental, EPE, Lisboa, Portugal.
3
Member of the Board of the Cardiovascular Risk and Prevention Group of the Portuguese Internal Medicine Society, Internal Medicine Department, Centro Hospitalar São João, Porto, Portugal.
4
Elect President of the Portuguese Society of Cardiology, Cardiovascular Unity, Hospital Lusíadas Lisboa, Lisboa, Portugal.
5
President of the Portuguese Association of Clinical Chemistry, Board of the Portuguese Society of Laboratory Medicine, Clinical analysis laboratory "Prof. Doutor Joaquim J, Nunes de Oliveira, Lda", Póvoa do Varzim, Portugal.
6
re. Germano de Sousa Group - Centro de Medicina Laboratorial, Pólo Tecnológico de Lisboa, Portugal.

Abstract

Even with the improvement in lifestyle interventions, a better control of cardiovascular (CV) risk factors, and improvements in CV outcomes, cardiovascular disease (CVD) still persists as the leading cause of morbidity and mortality in Portugal and Europe. Atherogenic dyslipidaemias, namely hypercholesterolaemia, have a crucial and causal role in the development of atherosclerotic CVD. The clinical approach of a patient with dyslipidaemia involves a watchful diagnosis, sustained in lipid and lipoprotein laboratory procedures, which must be harmonized and standardized. Standardization of lipid test results and reports, incorporating the total CV risk and the respective target and goals of treatment approach, guarantees that clinical guidelines and good clinical practices are followed and respected, increasing the reliability of lipid disorders screening, producing more accurate diagnoses and CV risk stratification, and improving the CV prevention and the achievement the desirable treatment goals.

KEYWORDS:

Cardiovascular risk; Clinical laboratory reports; Dyslipidaemia; Lipid goals; Standardization

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center